SynthesisFrontiers in immunology2026
The evolving landscape of
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: Publications from 2006 to 2025 were retrieved from the Web of Science Core Collection (WOSCC) and Scopus databases, which formed the core dataset for bibliometric analysis. Clinical trial data were independently supplemented from PubMed to assess translational progress. Multidimensional bibliometric analyses and visualization were performed using R-bibliometrix, VOSviewer and CiteSpace. Results: A total of 1,374 eligible publications were included, with an average annual growth rate of 15.71%, indicating a rapidly expanding field. The research landscape exhibits a hierarchical, stepwise distribution dominated by the United States, with active contributions from multiple countries. Utrecht University and the University of California system were the most prolific institutions. Frontiers-series journals serve as the major publication outlets. Knowledge structure analysis indicates a paradigm shift from fundamental immune mechanisms toward antibiotic resistance, biofilm biology, and immunometabolic regulation. Integration of PubMed clinical data revealed a critical translational gap, as despite advances in mechanistic research, most candidate vaccines and monoclonal antibody therapies failed to meet primary clinical endpoints. Conclusion: Research on
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.